X

Trial Profile

A Phase II Trial Evaluating Glofitamab, a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glofitamab (Primary) ; Obinutuzumab
Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms BiCAR

Most Recent Events

02 Jan 2024 Last checked against European Clinical Trials Database.
12 Dec 2023 Results(As of June 2nd) of the primary analysis from this study,presented at the 65th American Society of Hematology Annual Meeting and Exposition
25 Sep 2023 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com